Post by Exploration of Targeted Anti-tumor Therapy

This article unpacks the trade-offs between weekly, biweekly, and triweekly docetaxel for metastatic prostate cancer. Docetaxel is backbone therapy for mHSPC/mCRPC, yet optimal dosing remains unclear—especially for elderly & frail patients who need better tolerability. This pooled analysis of 11 studies (1,238 patients) delivers clear clinical takeaways: ✅ All schedules yield comparable PSA response rates ⏱ Triweekly dosing significantly prolongs time to treatment failure (+10.91 months vs weekly) ⚠ Higher hepatotoxicity & vomiting risk with biweekly/triweekly regimens 🤝 Weekly docetaxel delivers superior overall tolerability Core takeaway: Treatment selection must individualize efficacy vs toxicity profiles based on patient age, frailty, and comorbidities. Full article: https://lnkd.in/gdP5Dwe3 #ProstateCancer #GUOncology #Docetaxel #MedicalOncology #ClinicalResearch #NetworkMetaAnalysis